Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leukocyte-poor platelet-rich plasma
- Development stage
- Unknown
- Lead developer
- University Health Network
- Modality
- Cell Therapies
- Administration
- Intraarticular
01
Overview
Leukocyte-poor platelet-rich plasma (LP-PRP) is an autologous biological therapy being evaluated by the University Health Network (UHN) in Toronto for the treatment of knee osteoarthritis. Prepared from the patient's own peripheral blood using specialized separation systems like the Cervos KEYPRP Platelet Separator, LP-PRP contains a high concentration of platelets in a small volume of plasma, with the majority of pro-inflammatory leukocytes removed. Upon intra-articular injection, platelets undergo degranulation, releasing a variety of bioactive proteins including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). These factors modulate the intra-articular environment, promoting tissue repair, reducing inflammation, and potentially slowing the progression of cartilage degeneration. In the ABLE OA clinical trial (Phase II/III), LP-PRP is specifically studied as part of a combination regimen alongside micronized lipoaspirate (LAM).
- Brand names
- PurePRP
- Other names
- leukocyte-poor PRPautologous leukocyte-poor platelet-rich plasma
Beyond the preview
Go deeper on leukocyte-poor platelet-rich plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leukocyte-poor platelet-rich plasma.